Good morning all.
First, there is a contract win this morning from Cloudbuy (LON:CBUY).
with an Australian State Government (the "State") to provide an eprocurement marketplace
http://www.investegate.co.uk/cloudbuy-plc--cbuy-/rns/contract-win/201408120700048222O/
This is fantastic news as it validates much of the entire concept that Cloudbuy (LON:CBUY) has been pushing for years.
revenues will be derived via a transactional charge, calculated as a percentage of the value of spend. Based on the current procurement card spend, it is estimated that this could generate a fee of approximately AUD 900,000 per annum which could in due course rise to a maximum of AUD 7.2 million per annum.
Given that last year's full turnover was just £3m, this contract is significant.
The initial contract, which is for a minimum period of 6 months
suggests that the customer has an inexpensive exit if things don't work out.
If Cloudbuy (LON:CBUY) can deliver here then there is fantastic potential to deliver with other authorities in Australia and elsewhere.
Better Capital PCC (LON:BCAP) have got an interim management statement out. This is Jon Moulton's (listed) private equity operation. I'm mentioning it here as the shares are currently trading near a low for the year so perhaps represent an opportunity.
The problem is that the first Fund is performing badly. So unless the company can turn that around, the shares will likely continue to suffer as confidence in the team drains.
Digital media company Mirada (LON:MIRA) announces full-year results:
http://www.investegate.co.uk/mirada-plc--mira-/prn/final-results/20140812070000P9B28/
the company has attracted a reasonable level of private investor excitement recently. Sales down slightly and a £0.4m pre-tax loss. Outlook is very bullish:
The Tier One contract has expanded the pipeline of opportunities in Latin America and beyond. References are key in this market and we are already seeing the benefits as we seek to capitalise on recent successes.
Biotech Scancell Holdings (LON:SCLP) has some encouraging data out:
http://www.investegate.co.uk/scancell-hlds--sclp-/rns/synergy-of-scib1-with-checkpoint-inhibitors/201408120700048318O/
animals treated with a combination of SCIB1, Scancell's ImmunoBody® vaccine in development for the treatment of melanoma, and checkpoint inhibition (blockade of the PD-1 immune checkpoint pathway), showed enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.
announcements like this are encouraging to holders but typically with this type of firm, do not guarantee…
